Skip to Content

  • Search

View Additional Section Content

GOG-0241 – A GCIG Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/- NCI Supplied Agent: Bevacizumab (NSC 704865, IND 7921) Compared with Oxaliplatin and Capecitabine +/- Bevacizumab as First Line Chemotherapy in Patients with Mucinous Epithelial Ovarian or Fallopian Tube Cancer (MEOC).

Clinical Trial Categories

  • Ovarian Cancer
Contact
Hanjani Institute for Gynecologic Oncology at 215-885-0220

Location

  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details